Acurx Pharmaceuticals Inc

ACXP

Company Profile

  • Business description

    Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

  • Contact

    259 Liberty Avenue
    Staten IslandNY10305
    USA

    T: +1 917 533-1469

    https://www.acurxpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4

Stocks News & Analysis

stocks

Nvidia earns upgrade as AI buildouts accelerate

Demand for AI infrastructure shows no signs of slowing.
stocks

Weekly earnings wrap: FMG, WDS, COL and more

A closer look at the final major results from August reporting season.
stocks

Chart of the Week: Are US mega-cap stocks undervalued?

Opportunities emerge across US equities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,243.2084.80-0.91%
CAC 408,376.7585.64-1.01%
DAX 4026,383.2797.310.37%
Dow JONES (US)53,463.88113.52-0.21%
FTSE 10010,839.8538.27-0.35%
HKSE25,565.7487.23-0.34%
NASDAQ26,130.2021.10-0.08%
Nikkei 22566,131.98130.18-0.20%
NZX 50 Index13,880.05133.16-0.95%
S&P 5007,675.701.58-0.02%
S&P/ASX 2009,038.2078.20-0.86%
SSE Composite Index3,956.5744.051.13%

Market Movers